SiteOne Therapeutics, headquartered in Bozeman, Montana with a research team in San Francisco, California, is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (NaV1.7) inhibitors based on naturally occurring small molecules. Given the critical role that NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.
TypePrivate
HQBozeman, US
Founded2010
Websitesite1therapeutics.com
SiteOne Therapeutics was founded in 2010 and is headquartered in Bozeman, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

SiteOne Therapeutics Office Locations

SiteOne Therapeutics has an office in Bozeman
Bozeman, (HQ)
3 203 Enterprise Blvd
Show all (1)
Report incorrect company information

SiteOne Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2010

SiteOne Therapeutics total Funding

$17.8 m

SiteOne Therapeutics latest funding size

$15 m

Time since last funding

2 years ago

SiteOne Therapeutics investors

SiteOne Therapeutics's latest funding round in January 2017 was reported to be $15 m. In total, SiteOne Therapeutics has raised $17.8 m
View all funding rounds
Report incorrect company information

SiteOne Therapeutics News and Updates

SiteOne Therapeutics Appoints Scott Braunstein, MD to Board of Directors

BOZEMAN, Mont., Sept. 11, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced that Scott Braunstein, MD has been appointed to the Company's Board of Directors. Dr. Braunstein brings extensive...
Report incorrect company information

SiteOne Therapeutics Blogs

SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Pain

Potential applications in pain associated with ocular surgery, injury, and Dry Eye Syndrome BOZEMAN, Montana, Sept. 25, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced the company has been awarded a $1.4 mil…

SiteOne Therapeutics Appoints John Hunter, Ph.D. as Chief Scientific Officer

BOZEMAN, Montana, September 6th, 2018 — SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced the appointment of John Hunter, Ph.D., as Chief Scientific Officer. Dr. Hunter is a highly-accomplished pharmaceutical research and developm…

SiteOne Therapeutics Company Life and Culture

Report incorrect company information

SiteOne Therapeutics Frequently Asked Questions

  • When was SiteOne Therapeutics founded?

    SiteOne Therapeutics was founded in 2010.

  • Who are SiteOne Therapeutics competitors?

    Competitors of SiteOne Therapeutics include U.S. Stem Cell, Cannabis Sativa and Pfenex.

  • Where is SiteOne Therapeutics headquarters?

    SiteOne Therapeutics headquarters is located at 3 203 Enterprise Blvd, Bozeman.

  • Where are SiteOne Therapeutics offices?

    SiteOne Therapeutics has an office in Bozeman.

  • How many offices does SiteOne Therapeutics have?

    SiteOne Therapeutics has 1 office.